Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
- Report ID: GVR-1-68038-743-8
- Number of Report Pages: 100
- Format: PDF, Horizon Databook
- Historical Range: 2018 - 2022
- Forecast Period: 2024 - 2030
- Industry: Healthcare
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Liposomal Doxorubicin Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Liposomal Doxorubicin Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Liposomal Doxorubicin Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Liposomal Doxorubicin Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Doxil/Caelyx
4.3.1. Doxil/Caelyx Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Lipodox
4.4.1. Lipodox Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Myocet
4.5.1. Myocet Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Others
4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Liposomal Doxorubicin Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Liposomal Doxorubicin Market: Application Movement Analysis, 2023 & 2030 (USD Million)
5.3. Breast Cancer
5.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Ovarian Cancer
5.4.1. Ovarian Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. AIDS-Related Kaposi’s Sarcoma
5.5.1. AIDS-Related Kaposi’s Sarcoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Multiple Myeloma
5.6.1. Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Other Solid Tumors
5.7.1. Other Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Liposomal Doxorubicin Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Liposomal Doxorubicin Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacies
6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacies
6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Liposomal Doxorubicin Market: Regional Estimates & Trend Analysis
7.1. Liposomal Doxorubicin Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. China Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Australia Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. South Korea Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Recent Developments & Impact Analysis by Key Market Participants
7.8. Company Categorization
7.9. Company Heat Map Analysis
7.10. Company Profiles
7.10.1. Sun Pharmaceutical Industries Ltd.
7.10.1.1. Participant’s Overview
7.10.1.2. Financial Performance
7.10.1.3. Product Benchmarking
7.10.1.4. Recent Developments/ Strategic Initiatives
7.10.2. Johnson & Johnson Services, Inc.
7.10.2.1. Participant’s Overview
7.10.2.2. Financial Performance
7.10.2.3. Product Benchmarking
7.10.2.4. Recent Developments/ Strategic Initiatives
7.10.3. Merck & Co., Inc.
7.10.3.1. Participant’s Overview
7.10.3.2. Financial Performance
7.10.3.3. Product Benchmarking
7.10.3.4. Recent Developments/ Strategic Initiatives
7.10.4. Cipla
7.10.4.1. Participant’s Overview
7.10.4.2. Financial Performance
7.10.4.3. Product Benchmarking
7.10.4.4. Recent Developments/ Strategic Initiatives
7.10.5. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
7.10.5.1. Participant’s Overview
7.10.5.2. Financial Performance
7.10.5.3. Product Benchmarking
7.10.5.4. Recent Developments/ Strategic Initiatives
7.10.6. Lupin
7.10.6.1. Participant’s Overview
7.10.6.2. Financial Performance
7.10.6.3. Product Benchmarking
7.10.6.4. Recent Developments/ Strategic Initiatives
7.10.7. Cadila Pharmaceuticals
7.10.7.1. Participant’s Overview
7.10.7.2. Financial Performance
7.10.7.3. Product Benchmarking
7.10.7.4. Recent Developments/ Strategic Initiatives
7.10.8. SRS Life Sciences
7.10.8.1. Participant’s Overview
7.10.8.2. Financial Performance
7.10.8.3. Product Benchmarking
7.10.8.4. Recent Developments/ Strategic Initiatives
7.10.9. GSK plc.
7.10.9.1. Participant’s Overview
7.10.9.2. Financial Performance
7.10.9.3. Product Benchmarking
7.10.9.4. Recent Developments/ Strategic Initiatives
7.10.10. Pfizer Inc.
7.10.10.1. Participant’s Overview
7.10.10.2. Financial Performance
7.10.10.3. Product Benchmarking
7.10.10.4. Recent Developments/ Strategic Initiatives
7.10.11. Sanofi
7.10.11.1. Participant’s Overview
7.10.11.2. Financial Performance
7.10.11.3. Product Benchmarking
7.10.11.4. Recent Developments/ Strategic Initiatives
7.10.12. Sigma-Aldrich Co.
7.10.12.1. Participant’s Overview
7.10.12.2. Financial Performance
7.10.12.3. Product Benchmarking
7.10.12.4. Recent Developments/ Strategic Initiatives
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
